• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Idiopathic inflammatory myopathy
Abstract: The idiopathic inflammatory myopathies, especially dermatomyositis and polymyositis, are systemic autoimmune diseases with significant mortality and morbidity. Muscle weakness of the proximal muscles is the most common presenting clinical feature. Since idiopathic inflammatory myopathy is relatively uncommon, randomized control trials are scarce, and no evidence-based optimal treatment regimen has been defined. Corticosteroids are first-line treatment but many patients will require further immunosuppressive or immunomodulatory treatment. Methotrexate, azathioprine and mycophenolate mofetil are among the most comm...
Source: Medicine - March 1, 2014 Category: Internal Medicine Authors: Ruth Davies, Ernest Choy Tags: Other autoimmune disorders Source Type: research

Therapy of myositis.
Abstract Idiopathic inflammatory myopathy consists of dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM). At all stages of myositis, physiotherapy is effective in improving muscle strength, endurance and in maintaining joint motion. In DM and PM the therapy is initiated with glucocorticosteroids. Steroid-sparing agents (azathioprine, methotrexate and cyclosporin A) are added to prevent Cushing's syndrome or an unsatisfactory response. Therapy can also be escalated with intravenous immunoglobulins. Tacrolimus and mycophenolate mofetil (MMF) were effectiv...
Source: Zeitschrift fur Rheumatologie - April 1, 2013 Category: Rheumatology Authors: Keck AD, Walker UA Tags: Z Rheumatol Source Type: research

Clinical Spectrum and Course in Individuals with Intravascular Large B-Cell Lymphoma Affecting the Nervous System: A Case Series (P01.102)
CONCLUSIONS: Although IVLBL has distinct pathological features, its clinical presentation can be protean, ranging from mild myopathy to fulminant brain or multi-organ failure. The patient's optimal chance for survival relies on early pathological diagnosis and prompt, aggressive chemotherapy.Disclosure: Dr. Zhong has nothing to disclose. Dr. Oakes has nothing to disclose. Dr. Sonnen has nothing to disclose. Dr. Ransom has nothing to disclose. Dr. Longstreth has nothing to disclose. Dr. Mrugala has received personal compensation for activities with UCB Pharma, Sigma-Tau Pharmaceuticals, and Perceptive Informatics. Dr. Mruga...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Zhong, N., Oakes, P., Sonnen, J., Ransom, B., Longstreth, W. T., Mrugala, M. Tags: P01 Neuro-Oncology: Therapeutics Source Type: research

Pages: 1  2  3  4  5  6  7